Question 1

What are the most cited papers from Immune Biosolutions (Canada)?

Accepted Answer

The most cited paper from Immune Biosolutions (Canada) is "Safety and efficacy of inhaled IBIO123 for mild-to-moderate COVID-19: a randomised, double-blind, dose-ascending, placebo-controlled, phase 1/2 trial" (Bruno Maranda, Sébastien M. Labbé, Magali Lurquin et al., 2023), with 17 citations. Next come "Structure-based design of macrocyclic peptides to generate functional antibodies against G protein-coupled receptors" (1) and "A Randomized, Double-Blind, Dose-Ascending, Placebo-Controlled Phase 1-2 Trial of Inhaled IBIO123: A Monoclonal Antibodies Cocktail Treatment for Mild-To Moderate COVID-19 Illness" (1).

Question 2

Which research topics does Immune Biosolutions (Canada) publish most on?

Accepted Answer

By volume in 2022-now: Monoclonal and Polyclonal Antibodies Research, Long-Term Effects of COVID-19, COVID-19 Clinical Research Studies and Receptor Mechanisms and Signaling.

Question 3

Which fields of science does Immune Biosolutions (Canada) work in?

Accepted Answer

In all years, 75% of research at Immune Biosolutions (Canada) is in Health Sciences, 25% in Life Sciences. Its largest fields are Medicine (75%), Biochemistry, Genetics and Molecular Biology (25%).